3 unknown, 1 recruiting. 4 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Unknown 3, Recruiting 1 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CD123-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2019-11-12 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CLL1-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2021-05-19 |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia Nilotinib 150 MG [Tasigna], Imatinib 400mg - Chronic Myeloid Leukemia | Early Phase 1 | Unknown | Assiut University | 100 | 2017-12-01 | 2017-10-10 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Hematologic Neoplasms (3) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Leukemia (2) · Myeloproliferative Disorders (2) · Anemia, Aplastic (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Bone Marrow Diseases (4) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Neoplasms by Site (3) · Leukemia (2) · Myeloproliferative Disorders (2) · Anemia (1) · Blood Protein Disorders (1)
Imatinib Mesylate (1) · daratumumab (1) · nilotinib (1)
iCell Gene Therapeutics (2) · Assiut University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
China (2) · United States (1)
Fang Liu, MD, PhD (2) · Hongyu Zhang, MD, PhD (2) · Christian B Gocke, MD, PhD (1)